Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality

Abstract

Objective

To assess the prevalence of disease- and therapy-related complications and of the organ damage after a follow-up of 15 years or more in patients with primary antiphospholipid syndrome (PAPS).

Methods

Medical records of patients prospectively followed in our centre for at least 15 years were retrospectively reviewed.

Results

Thirty-five Caucasian patients (33 female, two male) with diagnosis of PAPS followed from 1984 to 2013 with a mean age at onset of 32 years (SD 8.17) and a median follow-up of 20.5 years (range 15–30) were included. The occurrence of systemic autoimmune disease was observed in 14% of patients. Haemorrhagic, infective and neoplastic events were recorded in 34%, 6% and 9% respectively. Organ damage was present in 20% of patients at the end of the follow-up (17% neurological and 3% renal) and was significantly associated with the occurrence of thrombotic events (p: 0.027), particularly arterial (p < 0.001). A 48-year-old patient died from sepsis.

Conclusion

During long-term follow-up of PAPS systemic autoimmunity is not unexpected. Organ damage progresses in a significant proportion of patients especially if they have suffered previous arterial events. Our study clearly shows the possible evolution of the disease and of organ damage, suggesting that optimal therapy and optimal prophylaxis of each PAPS patient should be carefully identified and strictly applied.

Keywords

Primary antiphospholipid syndrome outcome organ damage mortality

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Pierangeli

de Groot

Dlott

. ‘Criteria' aPL tests: Report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus 2011; 20: 182–190.

Erkan

Yazici

Sobel

. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 2000; 27: 2817–2821.

Cervera R, Serrano R, Pons-Estel GJ, et al., on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2014 (Epub ahead of print) doi:101136/annrheumdis-2013-204838.

Grika

Ziakas

Zintzaras

. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39: 516–523.

Tektonidou

Varsou

Kotoulas

. Cognitive deficits in patients with antiphospholipid syndrome: Association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med 2006; 166: 2278–2284.

Stoll

Seifert

Isenberg

. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248–254.

Barbhaiya M, Erkan D, Rodriguez-Almaraz E, et al. Utility of the Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index for antiphospholipid antibody (aPL) positive patients. [Abstract.] Arthritis Rheum 2011; 63(Suppl. S3).

Amigo MC, Barile LA, Barragan A, et al. Development and initial validation of a chronic damage index in patients with antiphospholipid syndrome. [Abstract.] Arthritis Rheum 2011; 63(Suppl:S3).

10.

Andreoli

Pregnolato

Burlingame

. Antinucleosome antibodies in primary antiphospholipid syndrome: A hint at systemic autoimmunity? J Autoimmun 2008; 30: 51–57.